Gavinchuk

LSD derivatives BetterLife Pharma (BETR.C) is a biotech company with an LSD derivative drug candidate, making it a slightly fringe psychedelics company, but a psychedelics company nonetheless. The company currently…
SPL026 Small Pharma (DMT.V), a psychedelics company focusing on DMT announced today it’s completed Phase 1 for its drug candidate SPL026, (a DMT derivative) for the treatment of Major…
Diverse clinics Ketamine One (MEDI.NE) announced it’s adding 2 more locations to its already bustling ketamine clinic network. Through an acquisition last week, Ketamine One gains control of Illumma…
Biting the hand that feeds you Nova Mentis Life Sciences (NOVA.C) director Steven Feldman has some interesting thoughts around vaccines, and as a life sciences company, I think it’s…
“My faith is with technology and with psychedelics. Politics aren’t going to take us much further. ” – Terence McKenna   September 20th, 2021 I dig Terence McKenna, but…
Episode 2 Earlier this year Mindmed (MNMD.Q) co-founder JR Rahn went on an epic selling spree, selling nearly 90% of his holdings without telling the public why until days…
It seems like every few days I stumble across a new name in the psychedelics industry I hadn’t heard before. Usually smaller deals just getting off the ground. But,…
$10b Reddit, the 19th most visited website on the internet has murmurs surrounding its potential IPO this year.   On August 12th Reddit confirmed with TechCrunch that it raised…
“In business, cash is oxygen” – Gary Vaynerchuk   Psychedelics is a cash-intensive business. Earlier in the week, I wrote about how clinical trials alone cost companies tens, sometimes…
Studying clinical studies For many psychedelics companies, clinical trials are the most expensive part of their business model and the reason they need to raise so much capital. Finding…